Satsuma Stock Is Trading Higher As STS101 Shows Favorable Pharmacokinetic Profile, Tolerability In Early-Stage Study

Satsuma Pharmaceuticals Inc STSA announced positive Pharmacokinetic and safety results from a Phase 1 trial of STS101 (dihydroergotamine (DHE) nasal powder).
The data showed that all three dose strengths (5.2 mg and two higher dose strengths) administered with Satsuma's nasal delivery device were well-tolerated and achieved the target pharmacokinetic profile.
Based on these results and other data, Satsuma is initiating its SUMMIT Phase 3 efficacy trial with the 5.2 mg dosage strength of STS101.
The trial will enroll approximately 1,400 migraine patients.
Two co-primary endpoints of the SUMMIT trial are freedom from pain and freedom from most bothersome symptoms at two hours after STS101 administration.
Topline results from the SUMMIT trial are expected in the second half of 2022.
In September 2020, a similar Phase 3 EMERGE trial with STS101 failed to achieve freedom from pain and the most bothersome symptom in migraine patients.
Price Action: STSA shares are up 8.08% at $5.35 during the premarket session on the last check Thursday.